Tuesday, November 10
Lunch & Learn:
Presented by David C. Weisman, MD
Director, ANA Clinical Research Center
Early this year, Biogen submitted a monoclonal antibody to the FDA as the first potential disease modifying treatment. While the data is controversial, this event heralds a new age in Alzheimer’s disease. On November 10, Dr. Weisman will provide an update on this emerging field and discuss upcoming prevention trials. Please join us for a brief talk followed by an open ended discussion.
Join us on Zoom. We welcome you to come, listen, and participate.